About this trial
Patients with heritable retinoblastoma are at risk to develop an intracranial brain tumor, which is often fatal. The investigators intend to look at the incidence and survival of trilateral retinoblastoma (which is a brain tumor that can either be located in the pineal gland or elsewhere in the brain) in retinoblastoma patients globally. All retinoblastoma patients from participating centers will be included. The investigators hypothesize that the apparent incidence of trilateral retinoblastoma (especially the usually later diagnosed pineal trilateral retinoblastoma) in low-income countries will be lower because of low chances of surviving the ocular tumors at about 50% and also because of possible under-diagnosis. Therefore, as retinoblastoma care improves in low-income countries the incidence of (pineal) trilateral retinoblastoma might go up. Knowledge about incidence and survival can help improve health practices in parts of the world where this might be needed. Therefore this global study firstly aims 1) to evaluate survival after trilateral retinoblastoma and factors influencing survival and 2) to evaluate incidence of trilateral retinoblastoma by country income level. The study will run from 2024 through 2027.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
patients diagnosed with retinoblastoma
Disqualifiers
none
Trial population
As many centers in the world will be/have been contacted to participate in this study to provide information about their population of retinoblastoma and trilateral retinoblastoma patients. This study will come as close as possible to an overview of this disease worldwide.
Trial design
Cohort
Prospective
Treatments tested in this trial
Incidence and survival of trilateral retinoblastoma and the differences globally
Diagnostic testThe detection and survival of trilateral retinoblastoma around the world and for instance differences between high- and low-income countries in terms of incidence and survival.
Treatment groups
Trial outcomes
Primary outcomes
Number of participants (retinoblastoma patients) that will be diagnosed with trilateral retinoblastoma (incidence)
The proportion of patients that be diagnosed with trilateral retinoblastoma in the included cohort of retinoblastoma patients
Overall and event-free survival after being diagnosed with trilateral retinoblastoma
The overall and event free survival of patients diagnosed with trilateral retinoblastoma in the included cohort of retinoblastoma patients.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.